Induced Regulatory T-Cell Composition for Dsg3-Targeted Pemphigus Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for pemphigus, an autoimmune blistering disease, are inadequate in effectively harnessing the immunosuppressive function of regulatory T cells, particularly those that specifically target desmoglein 3 (Dsg3), leading to insufficient therapeutic outcomes.
Innovation Solution
Inducible regulatory T cells are produced by stimulating human peripheral T cells with anti-CD3 antibodies and IL-2, followed by resting cultures, resulting in high expression of suppressive molecules like CTLA4, NT5E, ITGAE, AREG, CD172g, and CD26, and specifically targeting Dsg3.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for pemphigus, then general immunosuppression is provided, but specific targeting of desmoglein 3 (Dsg3) is insufficient
Solution Approach 1:
The patent applies local quality by differentiating regulatory T cells to exhibit specific functional characteristics targeting Dsg3. The induced regulatory T cells are engineered to express specific molecules (CTLA4, NT5E, ITGAE, AREG, CD172g, CD26) that enable them to specifically recognize and suppress Dsg3-positive cells, providing localized and specific immunosuppression rather than general immunosuppression.
Solution Approach 2:
The patent employs parameter changes by modifying the functional state of regulatory T cells through specific culture conditions and induction protocols. The cells are induced to express higher levels of suppressive molecules and acquire enhanced suppressive function, changing their immunological parameters to achieve more effective and specific suppression of the autoimmune response against Dsg3.
2Reliability
If regulatory T cells are induced with simple stimulation protocols, then induction is easier, but suppressive function and molecular expression are insufficient
Solution Approach 1:
The patent applies preliminary action by preparing regulatory T cells through a multi-step induction protocol that includes initial stimulation with anti-CD3 antibody, resting periods, and sequential culture steps. This preliminary conditioning of the cells before administration ensures they acquire high expression of suppressive molecules and robust suppressive function, making them therapeutically effective.
Solution Approach 2:
The induction protocol employs periodic action through alternating cycles of stimulation and resting periods. The cells are stimulated with anti-CD3 antibody, then allowed to rest, followed by further stimulation and resting. This periodic pattern of activation and recovery enables the regulatory T cells to progressively upregulate suppressive molecules and enhance their functional capacity.
Data Source
Figure 1~2b
Figure 3a~4b
Figure 5~6
AI summary
The present disclosure provides a medicament for treating or preventing pemphigus. More particularly, the present disclosure provides a pharmaceutical composition for treating or preventing pemphigus, the pharmaceutical composition containing, as an active ingredient, an induced regulatory T cell having at least one characteristic selected from the group consisting of CTLA4-positive, NT5E-positive, ITGAE (CD103)-positive, AREG-positive, CD172g-positive, and CD26-positive.